# Quanterix Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quanterix

- Industry: Medical Devices & Equipment
- Headquarters: Billerica, US
- Website: www.quanterix.com
- Total disclosed funding: $94M
- Latest round: Series D (Aug 3, 2017)
- Investors on record: 9

## About

Based in Massachusetts, US, and founded in 2007 by co-founder David Walt, Quanterix Corporation, f.k.a. Digital Genomics, Inc., a.k.a. Quanterix is a life sciences company that develops the Simoa HD-1 Analyzer, an automated instrument that examines critical biomarkers to detect and diagnose diseases. In March 2022, Quanterix Corporation raised grant funding led by the Alzheimer's Drug Discovery Foundation. The company is publicly listed on NASDAQ under the ticker symbol QTRX. As of May 2024, the company is led by its CEO, Masoud Toloue.

The company provides Simoa® Assay Kits that contain all the reagents necessary to run assays on the HD-1, HD-X, SR-X, or SP-X platforms for multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The SP-X platform is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays, while the HD-X platform is a protein detection platform, and the SR-X platform enables researchers to apply Simoa detection in an expanded range of applications.

Quanterix generates revenue from the sale of its products through direct field sales, support organizations, and distributors or sales agents in the life science research sector, primarily laboratories associated with academic and governmental research institutions as well as pharmaceutical, biotechnology, and contract research companies.

## Funding rounds

- Series D, Aug 3, 2017, $8.5M — T Rowe Price
- Series D, Mar 23, 2016, $46M — ARCH Venture Partners, Bain Capital, Trinitas Private Equity, Hercules Capital, Cormorant Asset Management
- Series C, Nov 15, 2012, $19M — ARCH Venture Partners, Flagship Pioneering, Bain Capital, bioMérieux, In-Q-Tel
- Series B, Aug 16, 2011, $6M — ARCH Venture Partners, Flagship Pioneering, Bain Capital
- Series A, Aug 25, 2008, $15M — ARCH Venture Partners, Flagship Pioneering, Bain Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C, Series D
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B, Series C
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series A, Series B, Series C, Series D
- bioMérieux — Series C
- In-Q-Tel (https://capitalatlas.ai/funds/in-q-tel) — Series C
- Trinitas Private Equity (https://capitalatlas.ai/funds/trinitas-private-equity) — Series D
- Hercules Capital (https://capitalatlas.ai/funds/hercules-capital) — Series D
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series D
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series D